A non-psychoactive, non-cannabinoid, cannabis flavonoid called FBL-03G might have the potential to treat pancreatic cancer as a brand new study finds out. Researchers from Dana Farber Cancer Institute and Harvard Medical School tested FBL-03G on multiple animal models. They looked for the impact it has on the progression of tumors. It showed the therapeutic efficacy in local and mestatic tumour progression of pancreatic cancer in these animal models.
The treatment involves a combination of the flavonoid as an immunoadjuvant that is being carried out with & without the radiotherapy. All this while the flavonoid is being delivered using smart radiotherapy biomaterials to keep it sustainable.
Pancreatic cancer is a very aggressive type of cancer which makes it hard to treat. Current options like: Chemotherapy, surgery and radiation/immunotherapy have limited succes as the survival rate of pancreatic cancer in a late state is around 5 years (Using these methods).
The therapeutic efficacy of FBL-03G
The researches of this study tried multiple experiments repeatedly. This resulted in a massively increased survival rate for animals with pancreatic cancer in comparison with other treatments on these animals.
The study proclaimed: ‘While ongoing studies are in progress to address the specific mechanism for this immunotherapy potential of this cannabis derivative, the possibility of leveraging such a therapy approach to treat metastasis or increase survival is significant, given that most pancreatic cancer patients are diagnosed already with a metastatic disease, with limited treatment options.
‘The FBL-03G results reveal a new potential non-cannabinoid cannabis derivative with major potential for consideration in further investigations in the treatment of pancreatic cancer, where new therapy options are urgently needed.’
The growth of tumors in other body parts
Another un-suspected susprise for the researches was a discovery that showed the cannabis flavonoid is also able to reduce tumour growth in different parts of the body that the cancer had spread to. They found out that the FBL-03G flavonoid, delivered by “smart radiotherapy biomaterials”, resulted in tumour growth inhibition both locally and in different parts of the body.
Finally the study noted:
“The FBL-03G payload used in this study is a flavonoid non-cannabinoid derivative of cannabis, and the potential to inhibit both local and metastatic tumour progression is remarkable, especially for pancreatic cancer, with a dismal five-year survival rate of 8%.”
The amount of researches and studies on flavonoids found in cannabis is very low and also quite new. This is mainly due the prohabition of cannabis in general. The legalization in many countries last years opened the doors for researchers and scientists to find out what this amazing plant has to offer!